Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Preston Mason

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
European Journal of Preventive Cardiology|September 22, 2025
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITChen Gurevitz, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABGSubodh Verma, Deepak L Bhatt, Ph Gabriel Steg, et al.
The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
Iscience|August 31, 2021
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19Andrew Kosmopoulos, Deepak L Bhatt, Gus Meglis, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
European Journal of Preventive Cardiology|September 22, 2025
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITChen Gurevitz, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABGSubodh Verma, Deepak L Bhatt, Ph Gabriel Steg, et al.
The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
Iscience|August 31, 2021
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19Andrew Kosmopoulos, Deepak L Bhatt, Gus Meglis, et al.
Pageof 10